Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 0.61 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.57 |
| ▸ | MPO | P05164 | 3/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 3/20 | 0.42 |
| ▸ | HTR2C | P28335 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | HTR1B | P28222 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25422319 | 0.83 | HTR2A (0.54) | HTR2ATRPM8MPOSLC6A4MAPT | |
| SCHEMBL31292986 | 0.83 | HTR2A (0.54) | HTR2ATRPM8MPOSLC6A4MAPT | |
| SCHEMBL20258550 | 0.83 | HTR2A (0.58) | HTR2ATRPM8MPOSLC6A4MAPT | |
| SCHEMBL7822537 | 0.83 | HTR2A (0.58) | HTR2ATRPM8MPOSLC6A4MAPT | |
| Hydrochloric Acid SCHEMBL21546049 | 0.83 | MPO (0.55) | HTR2ATRPM8MPOSLC6A4MAPT | |
| Hydrochloric Acid SCHEMBL21546041 | 0.82 | HTR2A (0.56) | HTR2ATRPM8MPOSLC6A4MAPT | |
| SCHEMBL15791149 | 0.82 | HTR2A (0.42) | HTR2ATRPM8SLC6A4HTR6TSHR | |
| SCHEMBL8190563 | 0.82 | HTR2A (0.56) | HTR2ATRPM8MPOSLC6A4MAPT | |
| SCHEMBL15791148 | 0.81 | HTR2A (0.41) | HTR2ATRPM8SLC6A4 | |
| SCHEMBL14095640 | 0.80 | HTR2A (0.57) | HTR2ATRPM8MAPTNPSR1HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| US-20130289083-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2013-10-31 | — | — | US | disclosed |
| EP-2227233-B1 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20090176773-A1 | Non-Peptidic Inhibitors of AKAP/PKA Interaction | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2009-07-09 | — | — | US | disclosed |
| US-20090176773-A1 | Non-Peptidic Inhibitors of AKAP/PKA Interaction | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2009-07-09 | — | — | US | disclosed |
| WO-2009073620-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-06-11 | — | — | WO | disclosed |
| US-20080200531-A1 | CDKI pathway inhibitors as inhibitors of tumor cell growth | SENEX BIOTECHNOLOGY, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200531-A1 | CDKI pathway inhibitors as inhibitors of tumor cell growth | SENEX BIOTECHNOLOGY, INC. | 2008-08-21 | — | — | US | disclosed |
| WO-2007133772-A2 | CDKI PATHWAY INHIBITORS AS SELECTIVE INHIBITORS OF TUMOR CELL GROWTH | SENEX BIOTECHNOLOGY, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | HTR2A 349/4885TRPM8 901/4885MPO 4663/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | HTR2A 2097/4885TRPM8 2675/4885MPO 4708/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | HTR2A 2097/4885TRPM8 2675/4885MPO 4708/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | HTR2A 223/4885TRPM8 1288/4885MPO 4322/4885 |
| US-20080200531-A1 | CDKI pathway inhibitors as inhibitors of tumor cell growth | CDK3, CDKL3, CCNI | HTR2A 4767/4885TRPM8 4498/4885MPO 4783/4885 |
| US-20090176773-A1 | Non-Peptidic Inhibitors of AKAP/PKA Interaction | PRKCH, AIP, PRKCE | HTR2A 2221/4885TRPM8 4563/4885MPO 3777/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | HTR2A 1906/4885TRPM8 2830/4885MPO 4309/4885 |
| US-20130289083-A1 | IDO Inhibitors | IDO1, IDO2, INMT | HTR2A 243/4885TRPM8 4080/4885MPO 1075/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | HTR2A 2187/4885TRPM8 2312/4885MPO 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.